FRAMINGHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical ...

This put -% of the company's publicly available shares short. Short interest in Arch Therapeutics Inc Corp (OOTC:ARTH) decreased during the last reporting period, falling from 280.30M to 275.20M. This ...

FRAMINGHAM, Mass., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical ...

FRAMINGHAM, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical ...

Life science company Arch Therapeutics has appointed Dr. Avtar Dhillon as board chair and Dr. Arthur Rosenthal as director. The company has also appointed Dr. Terrence W. Norchi as president & CEO.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

WELLESLEY, MA--(Marketwired - Jan 6, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™, obtained positive results from ...

SAWC Fall provides a venue to educate clinicians about AC5 Advanced Wound System, present case studies, and continue strategic meetings with wound care companies. FRAMINGHAM, Mass., Oct. 01, 2024 ...

FRAMINGHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today ...